The unveiling of a novel mechanism of resistance to immunotherapy targeting HER2
E-Mail IMAGE: Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, ICREA Professor, CIBERONC Investigator, Director of the Hospital del Mar Medical Research Institute (IMIM). view more Credit: VHIO Redirection of lymphocytes, via T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), is already approved to treat some hematologic malignancies. In solid tumors these immune-based strategies continue to fail. Research led by Joaquín Arribas, co-Program Director of Preclinical and Translational Research at VHIO, has now show...
Source: eurekalert.org